Ciliary Neurotrophic Factor

Summary

Ciliary Neurotrophic Factor (CHEMBL4298063) is a phase-3 clinical-stage unknown; indicated across 5 conditions including macular degeneration and telangiectasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298063
Name	Ciliary Neurotrophic Factor
Type	Unknown
Max phase	3

Also known as: Ciliary neurotrophic factor, Human ciliary neurotrophic factor, Human cntf, Nt-501, CILIARY NEUROTROPHIC FACTOR

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	Ciliary neutrophic factor receptor	Agonist

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
macular degeneration	2	MONDO:0003004	EFO:0009606
telangiectasis	2	MONDO:0001576	MONDO:0001576
retinitis pigmentosa	2	MONDO:0019200	MONDO:0019200
glaucoma	2	MONDO:0005041	MONDO:0005041
anterior ischemic optic neuropathy	1	MONDO:0006649	EFO:1000809

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	2
PHASE4	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06971939	PHASE4	RECRUITING	Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
NCT03316300	PHASE3	COMPLETED	A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A
NCT03319849	PHASE3	COMPLETED	A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B
NCT04577300	PHASE2	ACTIVE_NOT_RECRUITING	Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma
NCT00447980	PHASE2	COMPLETED	A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa
NCT01530659	PHASE2	COMPLETED	Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa
NCT01949324	PHASE2	COMPLETED	A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel
NCT01327911	PHASE1	COMPLETED	Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).